Barinthus Biotherapeutics plc has announced its strategic transformation focusing on immunology and inflammatory diseases, highlighting its promising immunotherapy VTP-1000 for celiac disease, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results